June 23, 2016Journal of Global OncologyOpen Access

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

View Full Paper

Ask AI

Bookmark

Why the study?

Does rivaroxaban prevent rethrombosis and reduce bleeding compared to LMWH or LMWH/VKA in cancer patients with VTE?

Population

41 adult patients with active cancer and venous thromboembolic events, median age 62.5 years, 51.2% male…

Comparison

Rivaroxaban for a median time of 5.5 months. vs Historical controls from previously published…

Design

Cohort

Follow-up

median 5.5 months

Authors

FXFlávia Dias XavierUniversidade de Brasília PHPaulo M. HoffTranslational Research in Oncology MBMaria Ignez BraghiroliTwitter (United States)

Discussion

Member takes

Implication

Rivaroxaban appeared comparable in safety and efficacy to LMWH for cancer-associated VTE; leaves open its role as affordable alternative pending randomized confirmation.

Structured PICO

Does rivaroxaban prevent rethrombosis and reduce bleeding compared to LMWH or LMWH/VKA in cancer patients with VTE?

Population

41 adult patients with active cancer and venous thromboembolic events (VTE), median age 62.5 years, 51.2% male. Most frequent tumor histology was adenocarcinoma (78%), and 87.8% had advanced disease.

Intervention

Rivaroxaban (oral direct factor Xa inhibitor) for a median time of 5.5 months.

Comparator

Historical controls from previously published data receiving low molecular weight heparin (LMWH) alone or followed by vitamin K antagonists (VKA).

Outcome

Efficacy (prevention of rethrombosis) and safety (absence of major and nonmajor bleeding).hard clinical

In this retrospective cohort of cancer patients with VTE, rivaroxaban appeared to be a safe, effective, and more affordable alternative to low molecular weight heparin.

Limitations

Retrospective analysis
Small sample size
Use of historical controls rather than a randomized comparator group

Cite This Study

Xavier et al. (2016) studied this question.

synapsesocial.com/papers/6a737d24007d73ca2ffb6604 https://doi.org/10.1200/jgo.2015.002527

View Full Paper

Ask AI

Bookmark

Implication

Rivaroxaban appeared comparable in safety and efficacy to LMWH for cancer-associated VTE; leaves open its role as affordable alternative pending randomized confirmation.

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider